

USCDI+ for Respiratory Illness

Matt Rahn and Liz Turi, ASTP Hilary Marston and Ali Abbasi, FDA

11/18/2024





Agenda

- Opening Remarks
- Background on USCDI/USCDI+
- Why do we need USCDI+ for ARDS?
- Project and Data Element Overview
- Questions
- Commenting and Next Steps

United States Core Data for Interoperability: USCDI Essentials

USCDI


Comprises a core set of data needed to support patient care and facilitate patient access using health IT.

Establishes a consistent baseline of harmonized data elements that can be broadly reused across use cases, including those outside of patient care and patient access.

Expands incrementally over time via a transparent, established, and collaborative process, weighing both anticipated benefits and industry-wide impacts.




USCDI+: Extending Beyond the USCDI



- Unique program and use case-specific data needs are sometimes not fully met by USCDI.
- ASTP's USCDI+ initiative helps government and industry partners build on USCDI to support specific program needs.
- Applies USCDI processes for submission and harmonization while focusing on programmatic priorities.
- Seeks to leverage programs and authorities across HHS to drive adoption.

USCDI and USCDI+





USCDI+ Relationships and Alignment

USCDI data is maintained in ONDEC. T information about data classes and data		-	regular basis; however, o	complete	
Data Type USCDI+ Data Element				Created 3mo ago	Updated 4d ag
Encounter Diagnosis					
Details Relationships	Comments				
■ Associated Relationships			Keyword Search	٩	
Data Element 🔺	Data Class	Use Case	Domain		
Encounter Diagnosis	Encounter Information	Cancer Overarching	Cancer		
Encounter Diagnosis	Encounter Information	Maternal Health Overarching	Maternal H	ealth	
Encounter Diagnosis	Encounter Information	Case Reporting	Public Hea	lth	
Encounter Diagnosis	Encounter Information	Quality Overarching	Quality		
Rows 1 - 4 of 4					

ASTP




Why we need USCDI+ for ARDS?

Hilary D. Marston, MD, MPH


Chief Medical Officer U.S. Food and Drug Administration

The COVID-19 pandemic highlighted the need for efficient evidence FDA generation

COVID-19 Hospitalizations in 2020



Data infrastructure is essential for evidence generation



U.S. Department of Health and Human Services Office of the Chief Data Officer

Data Strategy 2023-2028


Ç, 🔇

Use Case B: Preparedness & Incident Response

B.2 Create foundational infrastructure

Establish consistent data and system standards across preparedness categories (i.e. minimal data necessary, minimum standards for EHRs, USCDI+). Identify mechanisms to formalize and implement the standards.

Severe COVID causes Acute Respiratory Distress Syndrome (ARDS)




1 Other causes include transfusion, aspiration, or shock, but the ARDS definition excludes pulmonary edema is primarily from cardiogenic edema or fluid overload. Consensus definition according to: Matthay MA, et al., A New Global Definition of Acute Respiratory Distress Syndrome. Am J Respir Crit Care Med. 2024 FDA

1 Bellani G, Laffey JG, Pham T, et al. Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 Countries. JAMA. 2016



11



ARDS is one of the most common diseases faced in critical illness



FDA recognizes the potential of Real-World Data to accelerate evidence generation





Real-world data¹ are data relating to patient health status and/or the delivery of health care routinely collected from a variety of sources.

Real-world evidence is the clinical evidence about the usage and potential benefits or risks of a medical product derived from analysis of RWD. Real-world data, including Electronic Health Record (EHR) data, can be used to streamline clinical investigations, when deployed in fit-for-purpose study designs.

The EHR serves as the hub for data used to care for patients with critical illness








FHIR and USCDI+ can streamline uses of EHR data





Solving these challenges requires multi-agency engagement



FDA

USCDI+ ARDS: Project Overview



USCDI+ for Respiratory Illness: ARDS

Purpose: To create USCDI+ data element list and FHIR implementations for trials of interventions to treat ARDS

Scope:

- Data standards needed to evaluate the efficacy and safety of interventions for ARDS
- Clinical trials of therapeutic interventions, irrespective of the type of intervention, that take place in the ICU
- Data generated should be able to support regulatory applications to FDA, if the study design is fit-forpurpose

Exclusions:

- Trials for preventative measures, such as vaccines
- Care settings outside the ICU
- Data not collected in the EHR
- Prospective/interventional adverse event reporting

Pilot use case:

• Data extraction from the EHR, to an electronic data capture system (EDC) or registry focused on an intervention to treat severe acute respiratory failure

ASTP

High Level Timeline




Figure Legend

Process Product

Federal Partners and relevant programs





- USCDI+ for public health case reporting
- CDC Resp net
- CDER OneSource program: eSource capture used in I-SPY COVID-19 trial
- Cure ID EHR data extraction for SCCM Virus Registry
- RWD Standardization Project



- Common Data Element Repository
- Data COUNTS
- ARDS pneumonia and sepsis phenotyping consortium
- Data Element Repositories at individual ICs



Outside Stakeholders

Discussions held with

- ✓ Professional Societies
- ✓ Clinical Trial Investigators
- ✓ Clinicians Caring for patients with ARDS
- ✓ Health IT experts in trial data capture
- ✓ Registries

Emerging Themes

- ICU trials require a high volume of data
- EHR is the source of most trial data, but electronic source data capture remains challenging
- Low penetration of FHIR resources for research
- Ventilator settings are a huge gap for critical care trials, even though they are captured in EHR
 Institution specific workarounds exist
- Medication administration
 - Can be difficult to define/observe
- Need for structured capture of major clinical events
 - Not part of the usual workflow



USCDI+ ARDS: Data Set



Navigating USCDI+

HealthIT.gev

Q Home USCDI USCDI+ Log in

https://uscdiplus.healthit.gov/

United States Core Data for Interoperability (USCDI)+

USCDI+ is a service that ONC provides to federal partners who have a need to establish, harmonize, and advance the use of interoperable datasets that extend beyond the core data in the USCDI in order to meet agency-specific programmatic requirements. Learn more about USCDI+ on HealthIT.gov. If you have any questions, technical issues, or need to request access for a colleague, please email USCDI.Plus@hhs.gov.

A USCDI+ "Domain" is a common set of data elements required for interoperability for multiple scenarios and use cases governed by the same set of standards, policies and/or guidelines. (Example: Public Health)

A USCDI+ "Use Case" is a common set of data elements required to support a specific set of functions within a Domain. (Example: Resource Reporting/Situational Awareness)

A USCDI+ "Data Class" is an aggregation of various Data Elements by a common scenario or use case. (Example: Facility Level Data)

A USCDI+ "Data Element" is the most granular level at which a piece of data is exchanged. (Example: Facility Address)

New Data Element & Class (ONDEC) Submission System

USCDI+ Domains





USCDI+ Behavioral Health: Public Feedback Requested

Log in	
User name	
Password	
	۲

Forgot Password ?

Log in

Don't have an account? Create USCDI+ Account



USCDI+ Domains: Respiratory Illness

USCDI+ Domains



Т



Respiratory Illness Data Elements

Respiratory Illness This data element list aims to enhance our national capacity to conduct efficient trials for therapeutic interventions in patients with Acute Respiratory Distress Syndrome (ARDS) by providing data standards that allow for easier and seamless research on the treatment of ARDS. Details Comments Details Q Keyword Search Data Element Description Data Class Domain Admission Date/Time Date and time the patient was admitted to a treatment facility; e.g., Enrollment/Treatment/Outcome Other Use hospital Cases Adverse Event Harm to a patient resulting from medical care rather than the underlying Adverse Events Other Use disease that requires additional monitoring, treatment or hospitalization, Cases or that results in death. Adverse Event Onset Date The date on which the adverse event was first evident Adverse Events Other Use Cases Adverse Event Resolution The date on which the adverse event was resolved. Adverse Events Other Use Date Cases Bicarbonate (blood gas) Bicarbonate concentration in blood gas specimen Laboratory Other Use Cases Blood Gas Specimen type Type of specimen used to determine blood gas values. Options should Other Use Laboratory include arterial and venous Cases Body position This variable denotes the patient position (proned, supine) at the time of Respiratory Support Other Use recording Cases **Body Temperature** Temperature is a measure of the patient's ability to generate and get rid of Vital Signs Other Use heat. Cases Cardiac Arrest Whether the patient experienced a cardiac arrest Adverse Events Other Use Cases



Data Element – Details

ASTP

Admission Date/Time								
Details Relationships Comments								
Click on the Relationships tab for the Domain, Use Case, and Data Class valu	es.							
Admission Date/Time								
Data Element Name:								
Admission Date/Time								
Submission Status:	USCDI+ Level:							
Published								
Description:								
Date and time the patient was admitted to a treatment facility; e.g., hospit	al							
Additional Information:								
USCDI Information								
In USCDI:	Current USCDI Level:							
Yes	Level 0							

Data Element - Relationships

Details Relationship	Comments							
Associated Relationsh	ips	۲ ا	Keyword Search	Q				
Data Element 🔺	Data Class	Use Case	Domain					
Admission Date/Time	Enrollment/Treatment/Outcome	Respiratory Illness	Other Use Cases	S				
Admission Date/Time	Encounter Information	Case Reporting	Public Health					
Admission Date/Time	Encounter Information	Comprehensive Care	Behavioral Healt	h				



USCDI+ Respiratory Illness: Comments

Admission Date/Time

Details	Relationships	Comments	New	US	CDI+ Co	mm	nent															\heartsuit
			* Indic *Comr		required																	
			5	ð	Paragraph	~	В	Ι	E 3	F =		:= 1	= <	≥	9	H.	2	{;} <>				
					Period																	11
					e Cases - F		atory I	llness	- 2024-	11-18 to :	2025-	01-17	J						 			
	2																			S	ubmit	

Overview of USCDI+ Respiratory Illness Data Element List

7 Data Classes including **4 New Data Classes** (not included in USCDI V5) 61 Data Elements

7 Data Classes

- 1. Vital Signs
- 2. Respiratory Support (new)
- 3. Enrollment/Treatment/Outcome (new)
- 4. Adverse Events (new)
- 5. Medications
- 6. Laboratory
- 7. Intake and Output (new)



Questions on USCDI+ Respiratory Illness Data Element List

ASTP is seeking public comment on the USCDI+ Respiratory Illness Data Element List and requests specific attention to the following as a part of the review:

- Does the draft USCDI+ Respiratory Illness dataset include all the core data elements necessary to conduct clinical trials for ARDS? Are there any data elements that are not relevant to ARDS trials and should be removed?
- Are the data classes and elements detailed enough to support the accurate collection of ARDS data from EHR systems?
- Are the data elements and descriptions clear? What clarifications or updates are needed?
- Are there data elements in the USCDI+ Respiratory Illness dataset that might be too difficult to capture or share using current health IT systems?
- What are the potential barriers to collecting these data elements?
- How can we refine the data elements to reduce the documentation burden and better align with EHR workflows?







Questions and Discussion

How to Stay Involved

- REMINDER: Comments are due on the data element list on the <u>USCDI+ Platform</u> on January 17, 2025, by 11:59PM ET.
- ASTP will review public comments received and expects to publish a final version of the USCDI+ Respiratory Illness v1 in mid 2025.
- Questions? Contact USCDI.Plus@hhs.gov.

